Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call summary indicates strong financial performance, with revenue exceeding guidance and positive free cash flow. Additionally, the company has a solid cash position and improved net cash relative to debt. The Q&A section highlights strong demand across platforms and a stable competitive landscape. Despite some unclear management responses, the overall sentiment is positive, with optimistic guidance and a focus on profitability. However, the lack of new partnerships or significant strategic shifts keeps the rating from being strong positive.

Key Financial Performance

Revenue $106.4 million, up from the previous year; exceeded the top of the guided range.

Adjusted EBITDA Well ahead of guidance; benefited from early recognized PG revenue and solid expense control.

Free Cash Flow Approximately $3.1 million generated in the quarter.

Cash, Cash Equivalents, and Marketable Securities Totaled more than $234 million at the end of the quarter, improving net cash position by nearly $20 million year-over-year.

Net Cash Position More than $23 million relative to convertible notes, improved by nearly $20 million compared to last year.

Gross Margin Expected to approach 50% for the year; sequential decline attributed to a significant pull forward of performance guarantees in Q1.

Utilization-Based Revenue Approximately 32% of total revenue for the quarter, consistent with prior quarters.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

New Product Launch: Accolade has expanded its health and benefits services, leveraging AI to enhance human care teams.

Expert Medical Opinion: Accolade won a significant new deal for second MD, marking a competitive takeaway in the expert medical opinion space.

Market Expansion: Accolade's pipeline remains strong with a number of exciting new wins across strategic, enterprise, health plans, and government segments.

Customer Growth: The company is seeing strong demand across all segments, with a focus on expanding relationships with health plans.

Operational Efficiency: Accolade has adjusted its marketing spend to focus on the most efficient opportunities, which is already visible in the quarter's results.

Cost Management: The company generated positive free cash flow of approximately $3.1 million, aided by solid expense control.

Strategic Shift: Accolade is focusing on building a collaborative ecosystem that shares longitudinal data to improve healthcare experiences.

Focus on Profitability: The company is committed to achieving profitability while balancing revenue growth.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Competitive Pressures: Accolade is facing competitive pressures in the healthcare market, particularly from powerful incumbents. The company has noted a notable competitive takeaway in the expert medical opinion space, indicating that competition is strong and requires a differentiated vision to succeed.

Regulatory Issues: The company operates in a dynamic market that is subject to regulatory changes, which can impact their business model and profitability. They are focused on balancing revenue growth against profit objectives, which may be influenced by regulatory factors.

Supply Chain Challenges: There are challenges related to the supply chain, particularly in the healthcare sector, which can affect the availability of services and products. The company is adapting its marketing spend to focus on the most efficient opportunities, indicating a need to manage supply chain dynamics.

Economic Factors: Employers are facing significant increases in healthcare costs, which is pushing them to demand more rigorous ROI guarantees from service providers. This economic pressure is influencing how Accolade structures its offerings and pricing.

Market Dynamics: The selling season is described as a year-round process, but there is a concentration of activity in the summer and fall. The company is experiencing strong demand across various segments, but deployment timeframes can vary, affecting revenue recognition.

Retention Risks: Accolade's contracts are typically three years, and while they expect high retention rates, there is a risk associated with contracts that may not align with their profitability goals. They have previously identified contracts that were not consistent with their path to profitability.

Utilization Variability: The company is seeing variability in utilization rates across its direct-to-consumer and enterprise platforms, which can impact revenue. They are closely monitoring customer acquisition costs and lifetime value to manage this variability.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Customer Expansion: DeVry University has expanded health and benefits services, achieving employee satisfaction and keeping medical trend to roughly 2%.

Technology Integration: Accolade is focused on leveraging AI to augment human care teams and scale with business growth.

Market Positioning: Accolade aims to create a collaborative ecosystem sharing longitudinal data to improve healthcare experiences.

Sales Strategy: The selling season is year-round, with strong activity across strategic, enterprise, health plans, and government segments.

Operational Efficiency: Changes in office location strategy and marketing spend adjustments are aimed at improving profitability.

Q3 Revenue Guidance: Revenue expected in the range of $104 million to $107 million.

Q3 Adjusted EBITDA Guidance: Adjusted EBITDA loss expected between $3 million and $5 million.

Full-Year Revenue Guidance: Reiterating fiscal year 2025 revenue guidance of $460 million to $475 million.

Full-Year Adjusted EBITDA Guidance: Adjusted EBITDA expected to be positive between $15 million and $20 million.

Long-Term Financial Targets: Expecting to double adjusted EBITDA in each of the next two years.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

Cash Position: Cash, cash equivalents, and marketable securities totaled more than $234 million at the end of the second fiscal quarter.

Net Cash Position: Net cash position of more than $23 million relative to convertible notes.

Free Cash Flow: Generated positive free cash flow in the quarter of approximately $3.1 million.

Debt Management: Expect to generate positive cash flow on a full-year basis and plan refinancing or retirement of convertible notes due in April 2026.

Guidance for Fiscal Year 2025: Reiterating revenue guidance of $460 million to $475 million and adjusted EBITDA of positive $15 million to $20 million.

Performance Guarantees: Adjusted EBITDA benefited from solid expense control, including management of marketing spend.

Shareholder Return Strategy: The company is focused on driving profitability and managing costs effectively to enhance shareholder value.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Can you just talk about where kind of navigation is spotting in relative to other big priorities of corporates this year, whether it's GLP-1s or anything else?

A:In terms of interest in the market, oftentimes things like GLP-1s will actually spawn more interest in advocacy and primary care, because of the necessity for navigation in those complex care situations to be driven by primary care positions powered by advocacy teams and driving value.

Q:Just a follow-up question on that selling season. And, Raj, you talked about kind of start time, sometimes in January, sometimes subsequent to that. So just curious how your visibility is shaping up right here and anything else from a feedback from customers that you're hearing that's resonating?

A:What we're seeing is resoundingly strong demand across each of the core platforms and by that I mean expert medical opinion, primary care, particularly in the health plan space for both of those offerings, as well as advocacy and all of the associated platform connected revenues in the employer space.

Q:Just curious if you're willing to share any key observation in terms of how employers have opposed their benefits -- employee benefits this year versus last year?

A:In the health plan segment, we're exceptionally effective selling into partners. The strength of our relationships and the existing relationships in market give us some insulation from pricing pressures based on the long-term nature of the relationships.

Q:Hoping Steve you could give us the detail on the utilization based revenue in the quarter.

A:Usage-based revenue in the quarter was similar to how it's been tracking. Call it we're running around 35 or so percent of the total.

Q:Can you just comment, under the hood, if we look at the demand drivers there, any changes in these?

A:I wouldn't say there's any tangible change. There's ebbs and flows associated with changes in that demand cycle based on drug shortages, et cetera.

Q:Can you talk about the trusted partners ecosystem a bit more?

A:The reason they do that beyond the clinical rigor value, et cetera, is we actually integrate with those solutions.

Q:You called out in your prepared remarks a step-up in some expenses in the second-half of the year. How should we think about the bucketing and the cadence of those costs?

A:What I'm thinking about there is timing of marketing spend primarily around direct-to-consumer.

Q:Review of Unclear Management Responses

A:Management's responses lacked clarity on the specific impact of GLP-1s on the overall demand drivers and how the trusted partners ecosystem contributes to revenue.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

ACCD Transcript

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Positive10-8

Accolade, Inc. (ACCD) Q1 2025 Earnings Call Transcript

Unknown6-27

The earnings call presents a mixed picture: strong cash position and consistent growth in advocacy and usage-based revenues are positives, but lower revenue guidance and tempered growth in certain areas raise concerns. The Q&A reveals management's focus on derisking and profitability, but also highlights competitive pricing pressures and uncertainties in market dynamics. Overall, while there are positive aspects, the cautious outlook and revenue guidance adjustments suggest a neutral stock price movement.

Accolade, Inc. (ACCD) Q4 2024 Earnings Call Transcript

Positive4-26

Accolade's earnings call indicates strong revenue growth, improved EBITDA outlook, and effective partnerships, especially with Blue Shield of California. Despite a lack of clarity on some performance metrics, the overall sentiment is positive due to raised guidance, significant growth in platform-connected revenues, and strategic investments in technology and AI. The company's focus on expanding its healthcare navigation platform and improving operational efficiency further supports a positive outlook.

Accolade, Inc. (ACCD) Q3 2024 Earnings Call Transcript

Positive1-9

The earnings call summary shows strong financial performance with a 17% pro forma growth rate and a 20% target for fiscal 2025. Product development and business updates are positive, with AI tools enhancing margins. Market strategy is solid, with no delays in sales cycles and strong bookings. Financial health is stable, with early PG revenue recognition. Shareholder returns are not detailed, but overall sentiment is positive, supported by optimistic guidance and strong growth expectations across core segments.

ACCD Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.